Clinical Guides
Myocarditis
A clinically focused, India-adapted guide to suspected myocardial inflammation across chest-pain, arrhythmic and heart-failure presentations, including imaging, selective biopsy, activity restriction and cause-specific treatment.
MedNext Academy | 13 min read
Myocarditis
A clinically focused, India-adapted guide to suspected myocardial inflammation across chest-pain, arrhythmic and heart-failure presentations, including imaging, selective biopsy, activity restriction and cause-specific treatment.
Summary
Myocarditis is inflammatory injury of heart muscle with a spectrum ranging from clinically silent biomarker or imaging abnormalities to infarct-like chest pain, high-grade conduction disease, malignant ventricular arrhythmia, acute heart failure and fulminant cardiogenic shock. It is not synonymous with a raised troponin after infection, and it cannot be safely diagnosed by one ECG, echocardiogram or viral antibody result. The practical syndrome begins with three major presentations: chest pain, electrical instability, or heart failure and shock. Recent infection, autoimmune disease, cardiotoxic exposure, pregnancy, a family history of cardiomyopathy or sudden death, and immune checkpoint inhibitor therapy alter probability and urgency.
Initial assessment combines haemodynamic status, 12-lead ECG, serial cardiac troponin, natriuretic peptide, inflammatory and organ-function tests, echocardiography and exclusion of acute coronary and other mimics. Cardiac magnetic resonance is the key non-invasive tissue-characterisation test when feasible. Endomyocardial biopsy is not routine for every stable patient; it is most valuable when a high-risk or selected intermediate-risk presentation could represent a histological subtype that changes urgent therapy. Management treats shock, heart failure and arrhythmia while pursuing an aetiology. Immunosuppression is cause specific, not empirical treatment for uncomplicated presumed viral myocarditis. Exercise restriction and structured reassessment reduce avoidable arrhythmic risk. This reviewed draft has been reviewed by the MedNext Clinical Team by the MedNext Clinical Team and does not replace an acute cardiology pathway.
How Common Is It?
The true incidence of myocarditis is uncertain. Mild and asymptomatic disease is underdetected, sudden deaths may not undergo expert cardiac pathology, and older studies often required biopsy while newer cohorts include cardiac magnetic resonance diagnoses. Administrative codes mix suspected and confirmed disease. These differences make a single global or Indian rate misleading. Myocarditis occurs across the lifespan, with clinically recognised acute disease often reported in adolescents and younger adults and with a male predominance in several phenotypes. Older adults, pregnant or postpartum patients, children, people with autoimmune disease and patients receiving cancer therapy can present differently. Seasonal and outbreak associations depend on circulating infections and local testing.
Outcome is equally heterogeneous. Many uncomplicated chest-pain presentations recover clinically, yet residual late gadolinium enhancement can persist and may retain prognostic significance. A subset develops persistent left-ventricular dysfunction, inflammatory cardiomyopathy, recurrent symptoms, ventricular arrhythmia, advanced heart failure or death. Fulminant physiology, biventricular failure, sustained ventricular arrhythmia, advanced atrioventricular block and specific histologies such as giant-cell myocarditis confer much higher risk than an uncomplicated infarct-like presentation with preserved function. Referral-centre cohorts overstate severe outcomes, while outpatient series can miss later events. Vaccine- or infection-specific risk estimates must include age, sex, exposure denominator and background incidence. The clinically useful epidemiological principle is therefore phenotype-based risk stratification, not reassurance from the word viral or alarm from troponin alone.
Risk Factors
A recent viral or febrile illness is common but does not identify the pathogen within myocardium. Susceptibility may reflect genetic cardiomyopathy variants, and inflammation can unmask an inherited arrhythmogenic phenotype; ask about cardiomyopathy, unexplained heart failure, ICD implantation and sudden death in relatives. Autoimmune and inflammatory diseases, sarcoidosis, eosinophilic disorders and hypersensitivity drug reactions are recognised contexts. Pregnancy and the postpartum period broaden the differential to peripartum cardiomyopathy. Alcohol, stimulants, toxins and selected medicines can cause direct or inflammatory myocardial injury. Previous myocarditis increases concern when compatible symptoms recur.
Cancer immunotherapy deserves explicit attention. Immune checkpoint inhibitors can produce an early, rapidly progressive myocarditis, sometimes overlapping with myositis or myasthenia and sometimes with preserved ejection fraction. Combination checkpoint blockade, other cardiotoxic therapies and coexisting immune adverse events increase suspicion. New chest discomfort, dyspnoea, weakness, ptosis, dysphagia, troponin rise or conduction change during or soon after treatment requires urgent multidisciplinary evaluation.
In India, infectious exposure history should extend beyond a generic viral prodrome. Ask about dengue-compatible illness, scrub-typhus exposure or eschar, leptospirosis risk after floodwater or animal urine, enteric illness, diphtheria immunisation and respiratory infections when the systemic syndrome supports them. Tuberculosis usually enters through pericardial, disseminated or immune-suppressed presentations rather than as an assumed cause of isolated myocarditis. A positive TB immune test does not demonstrate myocardial infection. HIV, immunosuppression, travel and local outbreaks guide testing; indiscriminate serological panels generate false attribution.
Diagnosis
The diagnosis is probabilistic until clinical, imaging and sometimes tissue evidence align. Stabilise first and exclude time-critical mimics in parallel.
History
Define whether the dominant syndrome is chest pain, palpitations or syncope, or breathlessness and congestion. Ask about exertional intolerance, orthopnoea, oedema, fever, respiratory or gastrointestinal symptoms, rash, arthralgia, muscle weakness and neurological symptoms. Record the timeline after infection, vaccination, a new medicine or immune checkpoint inhibitor. Obtain autoimmune, pregnancy, postpartum, toxin and family histories. In India, ask about TB contact and constitutional symptoms, floodwater or animal exposure, rural or mite exposure, dengue-like illness and immunisation, but only order tests that fit the syndrome and illness day.
Examination
Measure serial blood pressure, pulse, respiratory rate, oxygen saturation, temperature, perfusion, mental state and urine output. Seek congestion, gallop rhythm, murmurs, a rub, pulmonary crepitations, raised JVP, hepatomegaly and oedema. Bradycardia, irregularity or tachycardia may expose conduction or ventricular arrhythmia. Examine for rash, arthritis, lymphadenopathy, muscle tenderness, ptosis or fatigability and systemic infection. Repeat examination because compensated myocarditis can deteriorate quickly.
Investigations
Obtain ECG, serial high-sensitivity troponin, natriuretic peptide, CBC, CRP, electrolytes, creatinine, liver tests, glucose and chest radiograph. Echocardiography assesses left and right ventricular function, wall motion, strain, filling, valves, thrombus and effusion; normal ejection fraction does not exclude myocarditis. Exclude acute coronary syndrome according to age and probability using angiography or CT where appropriate. CMR should use contemporary oedema and non-ischaemic injury criteria and report ventricular function, late enhancement pattern and pericardium. Rhythm monitoring depends on symptoms and risk. Reserve EMB for high-risk or selected cases where histology, immunohistochemistry and pathogen analysis could change treatment. Avoid routine viral serology; blood or site-specific tests should answer a plausible aetiological question.
Differential Diagnosis
Acute coronary syndrome is the first major mimic of infarct-like myocarditis. Both can produce chest pain, ST-T changes, regional wall-motion abnormalities and troponin elevation. Age does not exclude coronary thrombosis, spontaneous coronary artery dissection or embolism. Takotsubo syndrome, pulmonary embolism, acute aortic disease, sepsis-related myocardial injury, tachycardia-mediated dysfunction and supply-demand infarction are other urgent alternatives. Pericarditis with minor troponin release overlaps clinically, while predominant ventricular dysfunction supports perimyocarditis. Dilated, arrhythmogenic, hypertrophic or infiltrative cardiomyopathy may present during an inflammatory hot phase. Cardiac sarcoidosis, amyloidosis and iron or storage disease require phenotype-directed testing. Peripartum cardiomyopathy must be considered late in pregnancy and postpartum.
The infectious differential should be driven by the whole illness. Dengue, scrub typhus, leptospirosis, influenza, COVID-19, enteroviruses, HIV and bacterial sepsis can be associated with myocardial injury, but circulating antibodies or a positive respiratory test do not automatically prove myocardial invasion. In diphtheria, neuropathy and delayed cardiotoxicity may accompany the characteristic infection. Tuberculosis more commonly causes pericardial effusion or constriction; consider myocardial or disseminated involvement only with supporting imaging, microbiology, histology or disease elsewhere. Autoimmune myocarditis, giant-cell myocarditis, eosinophilic hypersensitivity, sarcoidosis and immune checkpoint inhibitor myocarditis are high-stakes because biopsy or immediate immunosuppression may change outcome. Skeletal muscle disease can elevate some biomarkers; renal impairment and critical illness complicate troponin interpretation. The final diagnostic note should state what has been excluded, what remains suspected and what finding would trigger biopsy or transfer.
Management
Place patients with haemodynamic or electrical instability in monitored acute care and involve an advanced heart-failure or mechanical-support centre early. Treat cardiogenic shock with careful ventilation, vasoactive support and temporary mechanical circulatory support when indicated and available; avoid repeated fluid loading when congestion or ventricular failure is present. Manage ventricular arrhythmia and high-grade block according to emergency rhythm guidance, using temporary pacing where necessary. Stable systolic dysfunction receives guideline-directed heart-failure therapy after blood pressure, renal function and congestion are assessed. Anticoagulation is not routine for myocarditis itself but may be required for atrial fibrillation, intracardiac thrombus or another standard indication. Pericarditic pain may respond to anti-inflammatory treatment, but NSAIDs should not be used casually in symptomatic heart failure.
Treatment of inflammation is aetiology specific. Do not give empirical corticosteroids for uncomplicated presumed viral or uncharacterised lymphocytic myocarditis. Early immunosuppression is critical in selected biopsy-defined or strongly suspected conditions such as giant-cell, eosinophilic, sarcoid and immune checkpoint inhibitor myocarditis, within specialist protocols and after appropriate infection consideration. The evidence for immunosuppression in ordinary virus-negative lymphocytic myocarditis remains incomplete and phenotype dependent. Antimicrobial treatment targets a proven or strongly supported infection; antitubercular treatment is not a diagnostic trial for isolated troponin elevation. Stop strenuous exercise during active disease. Reassess symptoms, ECG, biomarkers, ventricular function, CMR where indicated and rhythm or exercise response before return. Provide a written escalation plan because late arrhythmia can occur after apparent symptomatic improvement.
Prescribing Information
Medication choices follow the presenting complication and cause rather than a universal myocarditis prescription. In reduced ejection fraction, introduce evidence-based heart-failure medicines as haemodynamics and kidney function permit, checking potassium, creatinine and blood pressure after initiation and titration. Diuretics relieve congestion but do not treat inflammation; record weight and volume response. Beta-blockers may be inappropriate during shock, marked bradycardia or unstable conduction disease and are introduced only after stabilisation. Renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists and SGLT2 inhibitors require the same contraindication, pregnancy and monitoring review as in other heart-failure syndromes. Antiarrhythmic selection and device decisions should involve cardiology because myocardial recovery and arrhythmic substrate evolve over months.
NSAIDs or aspirin may be used for a pericarditic pain phenotype when ventricular function is preserved, but should be avoided or used cautiously in symptomatic heart failure. Colchicine belongs to the pericardial component, not routine isolated myocarditis therapy. Corticosteroid and other immunosuppressive regimens should follow the suspected histology, biopsy findings, infectious work-up and specialist pathway. Before sustained immunosuppression, assess tuberculosis, hepatitis and other infection risks, vaccination, pregnancy and drug interactions. Immune checkpoint inhibitor myocarditis requires immediate interruption decisions, monitored admission and high-dose intravenous corticosteroid treatment when likely, followed by response-guided taper; second-line agents have weak comparative evidence and require cardio-oncology consultation. Do not prescribe empirical antivirals, immunoglobulin or antitubercular therapy solely for a troponin rise. Medication reconciliation should identify cardiotoxic drugs, stimulants and non-prescribed supplements.
When to Refer
Transfer urgently to a centre with intensive cardiac and advanced heart-failure capability when there is shock, escalating inotrope need, biventricular failure, sustained ventricular arrhythmia, high-grade atrioventricular block, recurrent syncope, severe hypoxaemia, rising lactate or rapidly progressive dysfunction. Early transfer is safer than waiting for biopsy results after multiple-organ failure develops. Discuss temporary mechanical circulatory support before refractory shock. A centre receiving a possible fulminant case should have expertise in CMR, EMB interpretation, pacing, ventricular-arrhythmia management and access or transfer pathways for ECMO or ventricular support.
Stable patients still need cardiology referral when troponin elevation, ECG abnormality or ventricular dysfunction persists; CMR suggests extensive or septal late enhancement; symptoms recur; or the diagnosis remains uncertain after coronary exclusion. Refer for EMB when the clinical course or phenotype suggests giant-cell, eosinophilic, sarcoid, immune checkpoint inhibitor or other treatable histology, or when progressive cardiomyopathy does not respond as expected. Cardio-oncology referral is same-day for suspected checkpoint inhibitor toxicity. Rheumatology, infectious-disease, maternal-cardiology, genetics or neuromuscular input is selected from the phenotype.
In India, explicitly determine whether local services can provide urgent echo, serial troponin, telemetry and vasoactive care. If not, transfer before instability. Infectious presentations needing dengue, scrub typhus, leptospirosis, diphtheria, HIV or TB evaluation should use state and institutional pathways; do not delay cardiac support while waiting for send-away tests. Follow-up referral is not complete until a team owns repeat function, CMR and return-to-activity decisions.
Red Flags
Red flags are physiological and electrical, not simply the height of troponin. Hypotension, cool peripheries, confusion, oliguria, rising lactate, severe breathlessness, pulmonary oedema and escalating oxygen need suggest cardiogenic shock or mixed shock. Sustained ventricular tachycardia, ventricular fibrillation, new high-grade atrioventricular block, marked QRS widening, recurrent syncope or frequent complex ventricular ectopy require continuous monitoring and specialist management. Severe right-ventricular failure, biventricular dysfunction and rapidly falling ejection fraction worsen risk. Chest pain with regional ST changes or persistent ischaemic pattern must remain on an acute coronary pathway until adequately excluded. A normal early echocardiogram or modest troponin does not neutralise dangerous conduction disease.
Specific clinical patterns should accelerate biopsy or cause-directed therapy. Fulminant deterioration after a short prodrome raises concern for giant-cell or other severe inflammatory myocarditis. Rash, eosinophilia, fever and a new medicine suggest hypersensitivity or eosinophilic disease. Ventricular arrhythmia with conduction disease and extracardiac clues may indicate sarcoidosis. During immune checkpoint inhibitor treatment, new troponin rise, AV block, ventricular arrhythmia, heart failure, myalgia, weakness, ptosis, dysphagia or respiratory muscle symptoms may represent a lethal myocarditis-myositis-myasthenia overlap. In India, shock during dengue, scrub typhus, leptospirosis or sepsis can be multifactorial; do not attribute it to myocarditis without excluding hypovolaemia, bleeding, vasoplegia and other organ injury. After discharge, recurrent syncope, palpitations, chest pain, dyspnoea or reduced exercise tolerance requires prompt reassessment rather than reassurance.
Indian Clinical Context
Indian practice spans tertiary centres with CMR, advanced heart-failure support and expert EMB through to facilities without round-the-clock echocardiography or serial high-sensitivity troponin. The safest adaptation is a tiered pathway. Every suspected case needs physiological triage, ECG, cardiac biomarkers, basic organ tests and echocardiography where possible. Patients with shock, serious arrhythmia, block or ventricular dysfunction should be transferred early to a monitored centre. CMR is highly valuable but must not delay coronary reperfusion, pacing, shock support or transfer. EMB should be concentrated in centres that can obtain adequate tissue, perform histology and immunohistochemistry, direct microbial analysis appropriately and act on the result; a poorly handled biopsy can add risk without diagnostic value.
The infectious differential must reflect season, geography and syndrome. Dengue, scrub typhus, leptospirosis and severe respiratory or enteric infections can coexist with myocardial injury, especially during monsoon or outbreaks, but testing must be illness-day and exposure appropriate. Tuberculosis should be considered with pericardial effusion, constriction, disseminated disease, HIV or tissue evidence, not presumed from endemicity alone. Viral antibody panels are usually low value. Record vaccine timing without implying causality. International ESC and ACC documents provide the strongest contemporary myocarditis framework but arise mainly from European and North American systems; genetic testing, CMR, biopsy, wearable defibrillators and mechanical support may be inaccessible or unaffordable. Discuss these limitations honestly, seek regional referral options and never substitute empirical immunosuppression for unavailable diagnostics. Public-sector infectious services and state referral networks should be integrated into discharge planning.
NMC Competency Mapping
This topic integrates core Medicine competencies in chest-pain assessment, cardiovascular examination, ECG interpretation, heart failure, shock, arrhythmia, infection and rational therapeutics. A learner should recognise the chest-pain, arrhythmic and heart-failure presentations; obtain a timeline of infection, medicines, immunotherapy and family history; identify congestion, poor perfusion and conduction abnormalities; and construct a differential that includes acute coronary syndrome, pulmonary embolism, sepsis, Takotsubo syndrome and cardiomyopathy. The learner should explain what troponin, echocardiography, coronary imaging, CMR and EMB can and cannot establish, rather than equating one abnormal test with diagnosis.
At the application level, the student should triage stable versus fulminant disease, initiate monitoring, identify when pacing or shock support is needed and communicate an early referral. Prescribing competence means choosing heart-failure therapy around haemodynamics, avoiding inappropriate NSAIDs in symptomatic failure, and recognising that corticosteroids or other immunosuppression require a cause-specific specialist decision. India-relevant learning includes exposure-based evaluation of dengue, scrub typhus, leptospirosis, diphtheria, HIV and tuberculosis without indiscriminate panels. Counselling should cover medicine safety, warning symptoms, temporary activity restriction and the uncertainty of recovery. Internship entrustment extends to initial stabilisation and safe transfer; CMR interpretation, EMB, immunotherapy-toxicity management, advanced support and return-to-sport clearance remain supervised. Departments should align these outcomes with the current NMC cardiovascular, emergency and infectious-disease competencies rather than assigning a fabricated myocarditis-specific code.
Key Exam Pearls for NEET PG
Myocarditis presents as chest pain, arrhythmia or heart failure; fulminant myocarditis is defined clinically by haemodynamic or electrical instability rather than a troponin threshold. ECG findings are variable and can include ST-T change, low voltage, ectopy, bundle-branch or AV block. Troponin supports myocardial injury but neither confirms aetiology nor excludes myocarditis when normal. Echocardiographic ejection fraction may be preserved. CMR applies oedema-sensitive and non-ischaemic injury criteria; a non-ischaemic subepicardial or mid-wall late-enhancement pattern differs from the territorial subendocardial pattern of infarction. CMR supports a clinical diagnosis but does not provide histological subtype. EMB can identify lymphocytic, giant-cell, eosinophilic or sarcoid inflammation and selected pathogens; it is targeted to high-risk or treatment-changing cases, not performed routinely in every stable patient.
Giant-cell myocarditis is associated with rapid failure, ventricular arrhythmia and conduction block and generally requires urgent biopsy-guided immunosuppression. Eosinophilic myocarditis may follow drugs, allergy or systemic eosinophilic disease. Immune checkpoint inhibitor myocarditis often occurs early, may have preserved ejection fraction, and can overlap with myositis or myasthenia; stop-and-treat decisions are urgent and multidisciplinary. Routine viral serology is low yield, and immunosuppression is not empirical therapy for presumed viral disease. Treat heart failure and arrhythmias conventionally while pursuing cause. Restrict strenuous exercise in active myocarditis and reassess after clinical recovery, commonly around three to six months depending on phenotype, with ECG, biomarkers, imaging and rhythm or exercise evaluation. Sudden-death risk and device timing require reassessment after recovery rather than an automatic permanent ICD during the acute inflammatory phase.
Frequently Asked Questions
Can myocarditis be ruled out when the echocardiographic ejection fraction is normal?
No. A person can have chest-pain or arrhythmic myocarditis with preserved global ejection fraction. Echocardiography remains essential for function, effusion and haemodynamics, but CMR may detect oedema and non-ischaemic injury. Serial ECG, troponin and rhythm assessment are also guided by the presentation and risk features.
Does a recent viral infection and raised troponin prove viral myocarditis?
No. Acute coronary syndrome, pulmonary embolism, sepsis-related injury, Takotsubo syndrome and other cardiomyopathies can produce the same combination. A positive respiratory test or antibody identifies exposure or systemic infection, not necessarily myocardial invasion. Diagnosis requires a coherent clinical and imaging pattern and, selectively, biopsy.
When is endomyocardial biopsy appropriate in suspected myocarditis?
Biopsy is most useful in high-risk or selected intermediate-risk disease when identifying giant-cell, eosinophilic, sarcoid, immune checkpoint inhibitor or another histological subtype would change urgent treatment, or when progressive disease remains unexplained. It should be performed and processed by experienced teams; stable uncomplicated cases often undergo non-invasive assessment first.
When may exercise resume after an episode of myocarditis?
Strenuous exercise stops during active disease. Return is individualised, commonly after several months, only after symptoms have resolved and reassessment shows satisfactory biomarkers, ventricular function and rhythm status; CMR and exercise or ambulatory testing are used according to risk. Competitive athletes and patients with persistent enhancement or arrhythmia require specialist clearance.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic